Astera Labs, Inc. $ALAB Position Increased by Russell Investments Group Ltd.

Russell Investments Group Ltd. boosted its holdings in Astera Labs, Inc. (NASDAQ:ALAB – Free Report) by 9.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 155,991 shares of the company’s stock after buying an additional 13,004 shares during the quarter. Russell Investments Group Ltd.’s holdings in Astera Labs were worth $55,540,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in ALAB. Greenleaf Trust lifted its position in shares of Astera Labs by 1.8% during the 2nd quarter. Greenleaf Trust now owns 2,000 shares of the company’s stock valued at $966,000 after acquiring an additional 36 shares during the last quarter. Parkside Financial Bank & Trust boosted its stake in shares of Astera Labs by 74.5% during the 2nd quarter. Parkside Financial Bank & Trust now owns 96 shares of the company’s stock worth $46,000 after acquiring an additional 41 shares in the last quarter. Integrated Advisors Network LLC boosted its stake in shares of Astera Labs by 4.8% during the 3rd quarter. Integrated Advisors Network LLC now owns 983 shares of the company’s stock worth $350,000 after acquiring an additional 45 shares in the last quarter. Interchange Capital Partners LLC boosted its stake in shares of Astera Labs by 4.4% during the 3rd quarter. Interchange Capital Partners LLC now owns 1,187 shares of the company’s stock worth $423,000 after acquiring an additional 50 shares in the last quarter. Finally, Glenmede Trust Co. NA grew its holdings in shares of Astera Labs by 2.7% in the 1st quarter. Glenmede Trust Co. NA now owns 1,909 shares of the company’s stock worth $209,000 after acquiring an additional 51 shares during the last quarter. Institutional investors and hedge funds own 60.47% of the company’s stock.

Insider Transactions at Astera Labs

In related news, Director Stefan A. Dyckerhoff sold 8,994 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.96, for a total transaction of $2,472,990.24. Following the completion of the sale, the director directly owned 3,309 shares in the company, valued at approximately $909,842.64. This trade represents a 73.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Manuel Alba sold 183,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $280.13, for a total transaction of $51,263,790.00. Following the sale, the director owned 253,863 shares of the company’s stock, valued at approximately $71,114,642.19. This represents a 41.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 220,497 shares of company stock worth $62,043,303 in the last quarter. 10.40% of the stock is owned by corporate insiders.

Astera Labs Stock Performance

Shares of Astera Labs stock opened at $221.83 on Monday. The stock has a 50-day moving average price of $294.27 and a 200 day moving average price of $257.09. The company has a market cap of $38.77 billion, a P/E ratio of 88.38 and a beta of 3.86. Astera Labs, Inc. has a 1 year low of $97.89 and a 1 year high of $499.48.

Astera Labs (NASDAQ:ALAB – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.13. Astera Labs had a return on equity of 25.35% and a net margin of 29.64%. The firm had revenue of $584.90 million during the quarter, compared to analyst estimates of $550.78 million. During the same period last year, the company posted $0.49 EPS. The business’s quarterly revenue was up 153.6% compared to the same quarter last year. On average, equities analysts forecast that Astera Labs, Inc. will post 2.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

ALAB has been the topic of a number of recent research reports. Needham & Company LLC cut their target price on Astera Labs from $425.00 to $300.00 and set a “buy” rating on the stock in a research report on Wednesday, November 4th. Jefferies Financial Group upped their target price on Astera Labs from $270.00 to $450.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Wall Street Zen upgraded Astera Labs from a “hold” rating to a “buy” rating in a research report on Saturday, November 7th. Barclays increased their price target on Astera Labs from $200.00 to $325.00 and gave the company an “equal weight” rating in a research report on Monday, July 20th. Finally, Royal Bank Of Canada dropped their price target on Astera Labs from $500.00 to $400.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 4th. Thirteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $320.85.

View Our Latest Stock Analysis on Astera Labs

Top Astera Labs Stories

Here are a few of the latest stories about ALAB:

  • Positive Sentiment: An analyst raised the company’s FY2026 EPS forecast, a potentially supportive signal for earnings expectations. FY2026 EPS Forecast for Astera Labs Boosted by Analyst
  • Neutral Sentiment: Astera Labs presented at the BMO Capital Technology and Innovation Leaders Conference; the available report is a transcript and does not identify a specific new catalyst. BMO Capital Conference Transcript
  • Negative Sentiment: Recent coverage describes a mixed trading picture: record Q3 growth is being offset by heavier selling pressure. It also flags competition from Marvell and Credo, which could challenge Astera Labs’ growth. Mixed Trading After Record Q3 Growth

Astera Labs Profile

(Free Report)

Astera Labs, Inc. is a fabless semiconductor company that develops connectivity solutions for cloud and artificial intelligence infrastructure. Its products are designed to help move data among processors, accelerators, memory and other components in high-performance computing systems. The company’s portfolio includes Aries PCIe and CXL retimers, Taurus Ethernet smart cable modules, Scorpio fabric switches and Leo CXL memory connectivity controllers. Astera Labs also offers software tools to help customers configure and monitor its connectivity products.

Featured Articles

Want to see what other hedge funds are holding ALAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astera Labs, Inc. (NASDAQ:ALAB – Free Report).

Institutional Ownership by Quarter for Astera Labs (NASDAQ:ALAB)

Receive News & Ratings for Astera Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astera Labs and related companies with MarketBeat.com's FREE daily email newsletter.